losartan has been researched along with Infections, Orthomyxoviridae in 2 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, P | 1 |
| Gu, H | 1 |
| Zhao, Z | 1 |
| Wang, W | 1 |
| Cao, B | 1 |
| Lai, C | 1 |
| Yang, X | 1 |
| Zhang, L | 1 |
| Duan, Y | 1 |
| Zhang, S | 1 |
| Chen, W | 1 |
| Zhen, W | 1 |
| Cai, M | 1 |
| Penninger, JM | 1 |
| Jiang, C | 2 |
| Wang, X | 1 |
| Yan, Y | 1 |
| Liu, Q | 1 |
| Li, N | 1 |
| Du, J | 1 |
| Li, X | 1 |
| Li, C | 1 |
| Jin, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Apelin; ACE2 and Biomarkers of Alveolar-capillary Permeability in SARS-cov-2 (COVID-19).[NCT04632732] | 140 participants (Actual) | Observational [Patient Registry] | 2020-10-26 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for losartan and Infections, Orthomyxoviridae
| Article | Year |
|---|---|
Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury.
Topics: Acute Lung Injury; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; | 2014 |
Angiotensin II receptor blocker as a novel therapy in acute lung injury induced by avian influenza A H5N1 virus infection in mouse.
Topics: Acute Lung Injury; Angiotensin II Type 1 Receptor Blockers; Animals; Birds; Host-Pathogen Interactio | 2015 |